India, Nov. 6 -- Halozyme Therapeutics (HALO) announced that the U.S. FDA has granted accelerated approval for Johnson & Johnson's (JNJ) RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and an anti PD-(L)1 therapy.
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer that can be difficult to treat once it advances after standard therapies, leaving patients with limited treatment options.
The newly approved treatment is the first dual targeted therapy approved in this setting, designed to simultaneously target EGFR and MET, two proteins involved in cancer growth ...